Cargando…

Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines

BACKGROUND: Recurrence of hand, foot and mouth disease (HFMD) pandemics continues to threaten public health. Despite increasing awareness and efforts, effective vaccine and drug treatment have yet to be available. Probiotics have gained recognition in the field of healthcare worldwide, and have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, Lei Yin Emily, Too, Horng Khit Issac, Tan, Eng Lee, Chow, Tak-Kwong Vincent, Shek, Pei-Chi Lynette, Tham, Elizabeth, Alonso, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920999/
https://www.ncbi.nlm.nih.gov/pubmed/27341804
http://dx.doi.org/10.1186/s12985-016-0567-6
_version_ 1782439460665819136
author Ang, Lei Yin Emily
Too, Horng Khit Issac
Tan, Eng Lee
Chow, Tak-Kwong Vincent
Shek, Pei-Chi Lynette
Tham, Elizabeth
Alonso, Sylvie
author_facet Ang, Lei Yin Emily
Too, Horng Khit Issac
Tan, Eng Lee
Chow, Tak-Kwong Vincent
Shek, Pei-Chi Lynette
Tham, Elizabeth
Alonso, Sylvie
author_sort Ang, Lei Yin Emily
collection PubMed
description BACKGROUND: Recurrence of hand, foot and mouth disease (HFMD) pandemics continues to threaten public health. Despite increasing awareness and efforts, effective vaccine and drug treatment have yet to be available. Probiotics have gained recognition in the field of healthcare worldwide, and have been extensively prescribed to babies and young children to relieve gastrointestinal (GI) disturbances and diseases, associated or not with microbial infections. Since the faecal-oral axis represents the major route of HFMD transmission, transient persistence of probiotic bacteria in the GI tract may confer some protection against HFMD and limit transmission among children. METHODS: In this work, the antiviral activity of two commercially available probiotics, namely Lactobacillus reuteri Protectis (L. reuteri Protectis) and Lactobacillus casei Shirota (L. casei Shirota), was assayed against Coxsackieviruses and Enterovirus 71 (EV71), the main agents responsible for HFMD. In vitro infection set-ups using human skeletal muscle and colon cell lines were designed to assess the antiviral effect of the probiotic bacteria during entry and post-entry steps of the infection cycle. RESULTS: Our findings indicate that L. reuteri Protectis displays a significant dose-dependent antiviral activity against Coxsackievirus type A (CA) strain 6 (CA6), CA16 and EV71, but not against Coxsackievirus type B strain 2. Our data support that the antiviral effect is likely achieved through direct physical interaction between bacteria and virus particles, which impairs virus entry into its mammalian host cell. In contrast, no significant antiviral effect was observed with L. casei Shirota. CONCLUSIONS: Should the antiviral activity of L. reuteri Protectis observed in vitro be translated in vivo, such probiotics-based therapeutic approach may have the potential to address the urgent need for a safe and effective means to protect against HFMD and limit its transmission among children.
format Online
Article
Text
id pubmed-4920999
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49209992016-06-26 Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines Ang, Lei Yin Emily Too, Horng Khit Issac Tan, Eng Lee Chow, Tak-Kwong Vincent Shek, Pei-Chi Lynette Tham, Elizabeth Alonso, Sylvie Virol J Research BACKGROUND: Recurrence of hand, foot and mouth disease (HFMD) pandemics continues to threaten public health. Despite increasing awareness and efforts, effective vaccine and drug treatment have yet to be available. Probiotics have gained recognition in the field of healthcare worldwide, and have been extensively prescribed to babies and young children to relieve gastrointestinal (GI) disturbances and diseases, associated or not with microbial infections. Since the faecal-oral axis represents the major route of HFMD transmission, transient persistence of probiotic bacteria in the GI tract may confer some protection against HFMD and limit transmission among children. METHODS: In this work, the antiviral activity of two commercially available probiotics, namely Lactobacillus reuteri Protectis (L. reuteri Protectis) and Lactobacillus casei Shirota (L. casei Shirota), was assayed against Coxsackieviruses and Enterovirus 71 (EV71), the main agents responsible for HFMD. In vitro infection set-ups using human skeletal muscle and colon cell lines were designed to assess the antiviral effect of the probiotic bacteria during entry and post-entry steps of the infection cycle. RESULTS: Our findings indicate that L. reuteri Protectis displays a significant dose-dependent antiviral activity against Coxsackievirus type A (CA) strain 6 (CA6), CA16 and EV71, but not against Coxsackievirus type B strain 2. Our data support that the antiviral effect is likely achieved through direct physical interaction between bacteria and virus particles, which impairs virus entry into its mammalian host cell. In contrast, no significant antiviral effect was observed with L. casei Shirota. CONCLUSIONS: Should the antiviral activity of L. reuteri Protectis observed in vitro be translated in vivo, such probiotics-based therapeutic approach may have the potential to address the urgent need for a safe and effective means to protect against HFMD and limit its transmission among children. BioMed Central 2016-06-24 /pmc/articles/PMC4920999/ /pubmed/27341804 http://dx.doi.org/10.1186/s12985-016-0567-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Ang, Lei Yin Emily
Too, Horng Khit Issac
Tan, Eng Lee
Chow, Tak-Kwong Vincent
Shek, Pei-Chi Lynette
Tham, Elizabeth
Alonso, Sylvie
Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines
title Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines
title_full Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines
title_fullStr Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines
title_full_unstemmed Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines
title_short Antiviral activity of Lactobacillus reuteri Protectis against Coxsackievirus A and Enterovirus 71 infection in human skeletal muscle and colon cell lines
title_sort antiviral activity of lactobacillus reuteri protectis against coxsackievirus a and enterovirus 71 infection in human skeletal muscle and colon cell lines
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920999/
https://www.ncbi.nlm.nih.gov/pubmed/27341804
http://dx.doi.org/10.1186/s12985-016-0567-6
work_keys_str_mv AT angleiyinemily antiviralactivityoflactobacillusreuteriprotectisagainstcoxsackievirusaandenterovirus71infectioninhumanskeletalmuscleandcoloncelllines
AT toohorngkhitissac antiviralactivityoflactobacillusreuteriprotectisagainstcoxsackievirusaandenterovirus71infectioninhumanskeletalmuscleandcoloncelllines
AT tanenglee antiviralactivityoflactobacillusreuteriprotectisagainstcoxsackievirusaandenterovirus71infectioninhumanskeletalmuscleandcoloncelllines
AT chowtakkwongvincent antiviralactivityoflactobacillusreuteriprotectisagainstcoxsackievirusaandenterovirus71infectioninhumanskeletalmuscleandcoloncelllines
AT shekpeichilynette antiviralactivityoflactobacillusreuteriprotectisagainstcoxsackievirusaandenterovirus71infectioninhumanskeletalmuscleandcoloncelllines
AT thamelizabeth antiviralactivityoflactobacillusreuteriprotectisagainstcoxsackievirusaandenterovirus71infectioninhumanskeletalmuscleandcoloncelllines
AT alonsosylvie antiviralactivityoflactobacillusreuteriprotectisagainstcoxsackievirusaandenterovirus71infectioninhumanskeletalmuscleandcoloncelllines